Alpha Teknova, Inc. ( (TKNO) ) has released its Q2 earnings. Here is a breakdown of the information Alpha Teknova, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alpha Teknova, Inc. is a prominent company in the life sciences sector, specializing in the production of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics.
In its latest earnings report, Teknova announced a total revenue of $10.3 million for the second quarter of 2025, marking a 7% increase from the same period in the previous year. This growth represents the fourth consecutive quarter of year-over-year revenue increase, reinforcing the company’s positive trajectory.
Key financial highlights from the report include a significant improvement in gross profit, which rose to $4.0 million from $2.8 million in the previous year, driven by manufacturing efficiency gains. Operating expenses decreased to $7.4 million, and the net loss narrowed to $3.6 million compared to $5.4 million in the second quarter of 2024. Additionally, adjusted EBITDA improved to negative $0.8 million from negative $2.6 million, and free cash flow was negative $2.3 million, an improvement from negative $3.0 million in the previous year.
Looking ahead, Teknova’s management remains optimistic, reaffirming its revenue guidance for 2025, anticipating total revenue between $39 million and $42 million, and projecting a full-year free cash outflow of less than $12 million. This outlook reflects the company’s confidence in its strategic investments and operational capabilities to sustain growth.